Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliya PEF ablation with neoadjuvant therapy in resectable NSCLC
NCT05583188Phase 4Terminated
- Sponsor
- Galvanize Therapeutics
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Galvanize Therapeutics. Primary endpoint: Pathologic response. Started Feb 2023; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05583188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583188.